MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria’s Recent Lancet ID Publication Featured in devex Article
Sanaria's recent publication in the Lancet Infectious Diseases was featured in an devex article entitled "The long road to a malaria vaccine that’s safe during pregnancy." This piece highlights the outstanding efficacy and safety over two years in Malian women of childbearing potential including protection during pregnancy - without a booster dose!
First-of-its-kind vaccine expands malaria protection for pregnant women
On August 14th, 2024, The Lancet Infectious Diseases released a publication entitled: "Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials."
Indonesian collaborators and stake holders attend meeting in Jakarta to report successful results of trial of PfSPZ vaccines in Indonesian soldiers.
Overview: In 2022-2023, Sanaria® PfSPZ Vaccine and Sanaria® PfSPZ-CVac (CQ) malaria vaccines were assessed in a phase 2 clinical trial in Papua, Indonesia, against genetically diverse, naturally transmitted Plasmodium falciparum in malaria naïve, Indonesian military personnel. On July 17, 2024, the Faculty of Medicine, University of Indonesia (FMUI) hosted a scientific meeting in Jakarta, Indonesia attended by representatives of all the stakeholders to review the trial.
Sanaria Hosts Students from the National Student Leadership Conference
On June 20th and 27th, Sanaria hosted over 100 students from the National Student Leadership Conference to teach them about Sanaria and it's mission to eradicate malaria.
Sanaria® PfSPZ-LARC2 Vaccine the focus of a meeting at Germany’s biologics regulatory agency, the Paul-Ehrlich-Instit.
DZIF Workshop on Malaria Vaccine Development focuses on Sanaria® PfSPZ-LARC2 Vaccine
Sanaria Wins Best Logistics Technology and Cold Chain Delivery Award
On April 2nd, 2024, Sanaria Inc. won the Best Logistics Technology and Cold Chain Delivery Award at the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress in Washington, D.C.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.